Sumitomo Dainippon Pharma
Focus: Sumitomo Dainippon Pharma is a Japanese-headquartered pharmaceutical company specializing in small-molecule therapeutics across endocrinology, nephrology, and neurology. It operates as a public company with a heavily commercialized portfolio anchored by blockbuster franchises.
Profile data last refreshed 4h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Sumitomo Dainippon Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Sumitomo Dainippon Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
1 imminent
ONAPGO
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$508M Part DStable
Peak15.9yr
Dominant revenue driver (51% of company revenue); beta-3 agonist with 18-year patent runway supporting long-term stability.
Help build intelligence for Sumitomo Dainippon Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.